Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors

Oncologist

Volumn 8, Issue 2, 2003, Pages 174-186

  MacDonald, Tobey J ^a   Rood, Brian R ^a   Santi, Maria R ^a   Vezina, Gilbert ^a   Bingaman, Kimberly ^a   Cogen, Philip H ^a   Packer, Roger J ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Atypical teratoid rhabdoid tumor; Diagnosis; Medulloblastoma; Molecular genetics; Primitive neuroectodermal tumor; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; IMATINIB; LOBRADIMIL; LOMUSTINE; MAFOSFAMIDE; PACLITAXEL; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE; TAXANE DERIVATIVE; TOPOTECAN; VASCULOTROPIN RECEPTOR; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG RESEARCH; DRUG SCREENING; EMBRYONAL CARCINOMA; EPENDYMOBLASTOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INFANT; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; NEUROEPITHELIOMA; PRIORITY JOURNAL; RHABDOID TUMOR; TERATOMA; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; INFANT WELFARE; INFANT, NEWBORN; MOLECULAR BIOLOGY; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 0037261086     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-2-174     Document Type: Article

References (63)

1. Gurney JG, Bunin GR. CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries LAG, Kosary CL, Hankey BF et al., eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub No 99-4649. Bethesda: National Cancer Institute, 1999:51-63.
2. Becker LE, Giangaspero F, Rorke LB et al. Embryonal tumours. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 2000:123-148.
3. Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-442.
4. Zeltzer PM, Boyett JM, Finlay JL et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-845.
5. Coffin CM, Braun JT, Wick MR et al. A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990;3:164-170.
6. Pearl GS, Takei Y. Cerebellar "neuroblastoma": nosology as it relates to medulloblastoma. Cancer 1981;47:772-779.
7. Hart MN, Earle KM. Primitive neuroectodermal tumors of the brain in children. Cancer 1973;32:890-897.
8. Gould VE, Jansson DS, Molenaar WM et al. Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. Lab Invest 1990;62:498-509.
9. Segal RA, Goumnerova LC, Kwon YK et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994;91:12867-12871.
10. Kim JY, Sutton ME, Lu DJ et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711-719.
11. Grotzer MA, Janss AJ, Fung K et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027-1035.
12. Gilbertson RJ, Pearson AD, Perry RH et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-477.
13. Grotzer MA, Hogarty MD, Janss AJ et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-2433.
14. Aldosari N, Bigner SH, Burger PC et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-544.
15. Raffel C, Jenkins RB, Frederick L et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842-845.
16. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001;61:513-516.
17. Biegel JA, Janss AJ, Raffel C et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 1997;3:473-478.
18. Rood BR, Zhang H, Weitman DM et al. Hypermethylation of HIC-I and 17p allelic loss in medulloblastoma. Cancer Res 2002;62:3794-3797.
19. Biegel JA. Cytogenetics and molecular genetics of childhood brain tumors. Neuro-oncol 1999;1:139-151.
20. Bayani J, Zielenska M, Marrano P et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000;93:437-448.
21. Burnett ME, White EC, Sih S et al. Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system. Cancer Genet Cytogenet 1997;97:25-31.
22. Fruhwald MC, O'Dorisio MS, Dai Z et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer 2001;30:38-47.
23. MacDonald TJ, Brown KM, LaFleur B et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-152.
24. Packer RJ, Cogen P, Vezina G et al. Medulloblastoma: clinical and biologic aspects. Neuro-oncol 1999;1:232-250.
25. Kumar R, Achari G, Banerjee D et al. Uncommon presentation of medulloblastoma. Childs Nerv Syst 2001;17:538-542; discussion 543.
26. Erdem E, Zimmerman RA, Haselgrove JC et al. Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors. Neuroradiology 2001;43:927-933.
27. Figeroa RE, el Gammal T, Brooks BS et al. MR findings on primitive neuroectodermal tumors. J Comput Assist Tomogr 1989;13:773-778.
28. Deutsch M. Medulloblastoma: staging and treatment outcome. Int J Radiat Oncol Biol Phys 1988;14:1103-1107.
29. Saran FH, Driever PH, Thilmann C et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Int J Radiat Oncol Biol Phys 1998;42:959-967.
30. Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328:1725-1731.
31. Albright AL, Wisoff JH, Zeltzer PM et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 1996;38:265-271.
32. Kortmann RD, Kuhl J, Timmermann B et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000;46:269-279.
33. Lee M, Wisoff JH, Abbott R et al. Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting. Pediatr Neurosurg 1994;2:240-247.
34. Pollack IF, Polinko P, Albright AL et al. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 1995;37:885-893.
35. Cochrane DD, Gustavsson B, Poskitt KP et al. The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood. Pediatr Neurosurg 1994;20:19-29.
36. Catsman-Berrevoets CE, Van Donegan HR, Mulder PG et al. Tumour type and size are high risk factors for the syndrome of "cerebellar" mutism and subsequent dysarthria. J Neurol Neurosurg Psychiatry 1999;67:755-757.
37. Bouffet E, Bernard JL, Frappaz D et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int J Radiat Oncol Biol Phys 1992;24:79-85.
38. Packer RJ, Goldwein J, Nicholson HS et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J Clin Oncol 1999;17:2127-2136.
39. Ris MD, Packer R, Goldwein J et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 2001;19:3470-3476.
40. Dunkel IJ, Boyett JM, Yates A et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol 1998;16:222-228.
41. Lefkowitz IB, Rorke JB, Packer RJ et al. Atypical teratoid tumor of infancy: definition of an entity. Ann Neurol 1987;22:448a-449a.
42. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 1996;85:56-65.
43. Biegel JA, Rorke LB, Packer RJ et al. Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg 1990;73:710-714.
44. Burger PC, Yu IT, Tihan T et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 1998;22:1083-1092.
45. Olson TA, Bayar E, Kosnik E et al. Successful treatment of disseminated central nervous system malignant rhabdoid tumor. Am J Pediatr Hematol Oncol 1995;17:71-75.
46. Fisher BJ, Siddiqui J, Macdonald D et al. Malignant rhabdoid tumor of brain: an aggressive clinical entity. Can J Neurol Sci 1996;23:257-263.
47. Hilden JM, Watterson J, Longee DC et al. Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. J Neurooncol 1998;40:265-275.
48. Oka H, Scheithauer BW. Clinicopathological characteristics of atypical teratoid/rhabdoid tumor. Neurol Med Chir (Tokyo) 1999;39:510-517; discussion 517-518.
49. Ho DM, Hsu CY, Wong TT et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor/medulloblastoma. Acta Neuropathol (Berl) 2000;99:482-488.
50. Bhattacharjee M, Hicks J, Langford L et al. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol 1997;21:369-378.
51. Versteege I, Sevenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-206.
52. Biegel JA, Zhou J-Y, Rorke LB et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-79.
53. Kalpana GV, Marmon S, Wang W et al. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994;266:2002-2006.
54. Sevenet N, Lellouch-Tubiana A, Schofield D et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 1999;8:2359-2368.
55. Sevenet N, Sheridan E, Amram D et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999;65:1342-1348.
56. Packer RJ, Biegel JA, Blaney S et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. Am J Pediatr Hematol Oncol 2002;24:337-342.
57. Kalifa C, Hartmann O, Demeocq F et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992;9:227-233.
58. Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16:210-221.
59. Slavc I, Schuller E, Czech T et al. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998;38:213-218.
60. Young SW, Qing F, Harriman A et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996;93:6610-6615.
61. Packer RJ, Raffel C, Villablanca JG et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 2000;92:249-254.
62. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat Med 1996;2:561-566.
63. Huang E, Teh BS, Strother DR et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002;52:599-605.